[HTML][HTML] 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
J Vansteenkiste, L Crino, C Dooms, JY Douillard… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
[HTML][HTML] 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
B Besse, A Adjei, P Baas, P Meldgaard, M Nicolson… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
[HTML][HTML] 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
WEE Eberhardt, D De Ruysscher, W Weder… - Annals of …, 2015 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
[HTML][HTML] Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
KM Kerr, L Bubendorf, MJ Edelman, A Marchetti… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The Second …
consensus conferences to focus on specific issues in each type of tumour. The Second …
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
L Crino, W Weder, J Van Meerbeeck… - Annals of …, 2010 - annalsofoncology.org
Lung cancer represents the leading cause of cancer mortality worldwide, accounting for 1.2
million deaths each year. Improving survival in lung cancer is a major challenge for modern …
million deaths each year. Improving survival in lung cancer is a major challenge for modern …
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
M Majem, O Juan, A Insa, N Reguart, JM Trigo… - Clinical and …, 2019 - Springer
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few
years have seen the development of a new staging system, diagnostic procedures such as …
years have seen the development of a new staging system, diagnostic procedures such as …
Ten years of progress in non–small cell lung cancer
DS Ettinger - Journal of the National Comprehensive Cancer …, 2012 - jnccn.org
Lung cancer is the leading cause of cancer death in the United States in both men and
women. An estimated 226,160 new cases will be diagnosed in 2012, and 160,340 deaths …
women. An estimated 226,160 new cases will be diagnosed in 2012, and 160,340 deaths …
Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up
G D'addario, E Felip - Annals of oncology, 2009 - annalsofoncology.org
The crude incidence of lung cancer in the European Union is 52.5/100 000 per year, the
mortality 48.7/100 000 per year. Among men the rates are 82.5 and 77.0/100 000 per year …
mortality 48.7/100 000 per year. Among men the rates are 82.5 and 77.0/100 000 per year …
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
H Akamatsu, K Ninomiya, H Kenmotsu… - International journal of …, 2019 - Springer
According to rapid development of chemotherapy in advanced non-small cell lung cancer
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …